Skip to content
Skip to main content

Splice Bio awarded with a “Colaboración Público-Privada” grant

January 26, 2023May 20th, 2025

BARCELONA, January 26, 2023 – SpliceBio, a genetic medicines company on a mission to expand the universe of diseases that can be addressed with gene therapy, announced today that it has been awared a “Colaboración Público-Privada” grant from the Spanish Ministry of Science and Innovation (CPP2021-00899).

Related

June 11, 2025

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

March 13, 2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

December 12, 2024

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

Leave a Reply